Pathologica, Journal Year: 2024, Volume and Issue: 116(4), P. 222 - 231
Published: Sept. 1, 2024
The uPath PD-L1 (SP263) is an AI-based platform designed to aid pathologists in identifying and quantifying positive tumor cells non-small cell lung cancer (NSCLC) samples stained with the SP263 assay.
Language: Английский
American Society of Clinical Oncology Educational Book, Journal Year: 2024, Volume and Issue: 44(3)
Published: May 23, 2024
Chemoimmunotherapy is currently the preferred first-line treatment option for majority of patients with advanced non-small cell lung cancer without driver genetic alterations. Most these patients, however, will experience disease progression within first year after initiation and both their physicians be confronted dilemma optimal second-line treatment. Identification molecular targets, such as
Language: Английский
Citations
11
European Journal of Clinical Pharmacology, Journal Year: 2025, Volume and Issue: unknown
Published: Jan. 22, 2025
Language: Английский
Citations
1
Journal of Experimental & Clinical Cancer Research, Journal Year: 2023, Volume and Issue: 42(1)
Published: Oct. 21, 2023
Alterations in several tripartite motif-containing (TRIM) family proteins have been implicated the pathogenesis of lung cancer. TRIM28, a member TRIM E3 ligase family, has associated with tumorigenesis, cell proliferation, and inflammation. However, little is known about TRIM28 expression its role immune microenvironment non-small cancer (NSCLC).We assessed clinical significance tissue microarrays TCGA cohorts. We investigated function syngeneic mouse tumor models, KrasLSL-G12D/+; Tp53fl/fl (KP) model, humanized mice. Immune composition was analyzed using flow cytometry immunohistochemistry.Our findings revealed positive correlation between infiltration suppressive myeloid-derived suppressor cells (MDSCs) NSCLC. Moreover, silencing enhanced efficacy anti-PD-1 immunotherapy by reshaping inflamed microenvironment. Mechanistically, we demonstrated that could physically interact receptor-interacting protein kinase 1 (RIPK1) promote K63-linked ubiquitination RIPK1, which crucial for sustaining activation NF-κB pathway. Mutagenesis domain corroborated essential activity TRIM28-mediated activation. Further experiments upregulate CXCL1 activating signaling. bind to CXCR2 on MDSCs their migration knockdown increased responsiveness therapy immunocompetent mice, characterized CD8+T tumor-infiltrating lymphocytes decreased MDSCs.The present study identified as promoter chemokine-driven recruitment through RIPK1-mediated activation, leading suppression infiltrating activated development resistance. Understanding regulation MDSC provides insights into association signaling an immunosuppressive These may inform combination therapies enhance effectiveness checkpoint blockade
Language: Английский
Citations
19
Translational Lung Cancer Research, Journal Year: 2024, Volume and Issue: 13(5), P. 1121 - 1136
Published: May 1, 2024
Abstract: Non-small cell lung cancer (NSCLC) is a malignant that with high incidence, recurrence, and mortality rates in human beings, posing significant threats to health. Moreover, effective early diagnosis of NSCLC remains limited primarily by the lack accurate biomarkers. Therefore, there an urgent need understand mechanisms underlying pathogenesis treatment failure. Methyltransferase-like 3 (METTL3) prototypical member family which its members transfer methyl groups. It has been implicated modulating NSCLC, as well conferring resistance therapeutics. The targeting METTL3 for reported. However, relationship between be demonstrated. In this review, we discuss relevant interrelationships summarising studies on pathogenesis, therapeutic resistance, clinical applications. Current research suggests upregulation expression propels tumorigenesis, progression, NSCLC. propose excellent candidate biomarker prognosis. Therapeutic potential treatment. This review provides summary association would valuable reference both basic research.
Language: Английский
Citations
7
Annals of Oncology, Journal Year: 2024, Volume and Issue: unknown
Published: Oct. 1, 2024
Language: Английский
Citations
7
Frontiers in Immunology, Journal Year: 2024, Volume and Issue: 14
Published: Jan. 12, 2024
Treatment of non-small-cell lung cancer (NSCLC) has entered the immunotherapy era, marked by significant survival improvements due to use immune checkpoint inhibitors (ICIs). However, owing factors, such as disease progression, long-term use, and side effects, some patients discontinue immunotherapy, resulting in limited subsequent treatment option a negative impact on their quality life. We have collected relevant data which reveal that ICI rechallenge may be an effective clinical strategy. many factors affect efficacy rechallenge, including patient characteristics, initial drugs, duration, efficacy, toxicity, effects. Additionally, effects mechanisms reversing drug resistance play crucial roles. Identifying suitable candidates, optimizing plans enhancing minimizing toxicity adverse rechallenges are pressing needs. Addressing these issues can provide guidance for better serve patients. This review focuses considerations strategies therapy NSCLC.
Language: Английский
Citations
4
Therapeutic Advances in Medical Oncology, Journal Year: 2025, Volume and Issue: 17
Published: Jan. 1, 2025
Background: For non-small-cell lung cancer (NSCLC) patients who progressed after first-line chemotherapy, immunotherapy targeting programmed cell death (ligand) 1 has shown promising activity. However, the activity is relatively limited in harboring epidermal growth factor receptor (EGFR) mutations. Objectives: This study aimed to evaluate efficacy and safety of camrelizumab plus famitinib previously treated with locally advanced metastatic NSCLC. Design: A single-center, single-arm, phase II study. Methods: Previously NSCLC were enrolled receive (200 mg, administered intravenously every 3 weeks) (20 orally once daily). Patients EGFR mutation genes had received at least one tyrosine kinase inhibitor no more than two lines chemotherapy regimen before enrollment. The other on or without primary endpoint was objective response rate (ORR) per RECIST v1.1 by investigator. Results: Our encompassed 23 between October 2019 2022. all patients, confirmed ORR 30.4%, disease control 95.7%. median progression-free survival (PFS) 6.9 months (95% CI: 4.9 months–not reached). overall (OS) not reached. 1- 2-year OS rates 85.6% 71.8%–100.0%) 56.8% 37.7%–85.7%). Especially, for 6 genetic aberrations, 33.3%, PFS 10.3 1.8–18.8 months), 20.3 0.8–39.8 months). most common grade above treatment-related adverse events platelet count decreased, white blood hypertension. No unexpected reported. Conclusion: Camrelizumab demonstrated encouraging clinical a manageable profile results warranted further validation. Trial registration: Chinese Clinical Registry identifier: ChiCTR1900026641.
Language: Английский
Citations
0
BMJ Open, Journal Year: 2025, Volume and Issue: 15(1), P. e093374 - e093374
Published: Jan. 1, 2025
Lung cancer is the leading cause of cancer-related mortality globally, with non-small cell lung (NSCLC) comprising majority cases. For advanced NSCLC, immunotherapy offers substantial survival benefits but often accompanied by severe immune-related adverse events symptoms, significantly affecting health-related quality life (HRQoL). Routinely collection patient-reported outcomes (PROs) followed automated alerts has been shown to improve overall and HRQoL for cancers. However, there limited evidence PRO-based symptom monitoring on NSCLC during immunotherapy. This study proposes an electronic tracking intervention, integrated reactive nudges (PRO-NET) patients receiving in China. Secondary objectives include assessing effect PRO-symptom survival, physical function, control, mental health, cost-effectiveness implementation fidelity. The PRO-NET a two-arm, parallel randomised controlled trial. will enrol at least 300 undergoing Participants be randomly assigned either intervention or control group ratio 1:1 via programme. involves weekly PROs sent directly patients, combined over 6-month period. Patients follow usual care not trigger alerts. Both groups receive outcome assessments baseline, 3 months 6 months. Primary focuses HRQoL, while secondary burden, Differences between compared using general linear mixed model, accounting potential confounding. was approved Institutional Review Board Peking University protocol 21 July 2024 (No. IRB 00001052-24066). based V2.0, protocol. results this disseminated through peer-reviewed publications academic conferences. ChiCTR2400088408.
Language: Английский
Citations
0
Frontiers in Immunology, Journal Year: 2025, Volume and Issue: 16
Published: March 6, 2025
The aim of this study is to develop and validate a predictive model for predicting survival in individual advanced non-small cell lung cancer patients by integrating basic patient information clinical data. A total 462 with collected from Shanxi Cancer Hospital were randomly assigned (in 7:3 ratio) training cohort an internal validation cohort. Independent factors affecting patients' 3-year screened models created using single-factor followed multifactor Cox regression analysis. Evaluate the performance consistency index (C-index), calibration curves, receiver operating characteristic curves (ROC) decision curve analysis (DCA). who received chemotherapy alone those combined immunotherapy statistically paired propensity score matching between two groups, subgroup analyses performed among variables. better prognostic was nomogram chart visualizing drawn. Based on median risk cohort, all individuals categorized into high- low-risk high-risk group having worse OS both cohorts (P<0.05). results showed that versus NSCLC affected OS. developed predict cancer. demonstrated superior alone.
Language: Английский
Citations
0
European Journal of Medicinal Chemistry, Journal Year: 2025, Volume and Issue: 289, P. 117442 - 117442
Published: March 12, 2025
Language: Английский
Citations
0